tradingkey.logo
tradingkey.logo
Search

AxoGen Inc

AXGN
Add to Watchlist
43.320USD
-1.220-2.74%
Close 09-23 16:00ET
2.33BMarket Cap
LossP/E TTM

About AxoGen Inc Company

Axogen, Inc. is focused on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. It offers repair solutions for surgeons and healthcare providers. Its portfolio of products includes Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard HA+ Nerve Protector, Axoguard Nerve Cap, and Avive+ Soft Tissue Matrix. Avance Nerve Graft is a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves. The Axoguard Nerve Connector is a porcine (pig) submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves. Axoguard Nerve Protector is a porcine submucosa ECM product used to wrap and protect damaged peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments. Axoguard HA+ Nerve Protector consists of a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating.

AxoGen Inc Profile

Ticker SymbolAXGN
Company nameAxoGen Inc
IPO dateDec 17, 1986
CEODale (Michael Donald)
Number of employees451
Security typeOrdinary Share
Fiscal year-endDec 17
Address13631 Progress Blvd.
CityALACHUA
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code32615
Phone13864626817
Websitehttps://www.axogeninc.com/
Ticker SymbolAXGN
IPO dateDec 17, 1986
CEODale (Michael Donald)

Company Executives of AxoGen Inc

Name
Name/Position
Position
Shareholding
Change
Mr. Erick Wayne DeVinney
Mr. Erick Wayne DeVinney
Chief Innovation Officer
Chief Innovation Officer
237.78K
+18.45%
Mr. Erick Wayne DeVinney
Mr. Erick Wayne DeVinney
Chief Innovation Officer
Chief Innovation Officer
237.78K
+18.45%
Mr. Erick Wayne DeVinney
Mr. Erick Wayne DeVinney
Chief Innovation Officer
Chief Innovation Officer
237.78K
+18.45%
Mr. Jens Schroeder Kemp
Mr. Jens Schroeder Kemp
Chief Marketing Officer
Chief Marketing Officer
64.95K
-6.16%
Mr. Jens Schroeder Kemp
Mr. Jens Schroeder Kemp
Chief Marketing Officer
Chief Marketing Officer
64.95K
-6.16%
Mr. Jens Schroeder Kemp
Mr. Jens Schroeder Kemp
Chief Marketing Officer
Chief Marketing Officer
64.95K
-6.16%
Mr. Paul G. Thomas
Mr. Paul G. Thomas
Independent Chairman of the Board
Independent Chairman of the Board
28.93K
+65.23%
Mr. Paul G. Thomas
Mr. Paul G. Thomas
Independent Chairman of the Board
Independent Chairman of the Board
28.93K
+65.23%
Mr. Paul G. Thomas
Mr. Paul G. Thomas
Independent Chairman of the Board
Independent Chairman of the Board
28.93K
+65.23%
Ms. Amy A. Mcbride-Wendell
Ms. Amy A. Mcbride-Wendell
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Erick Wayne DeVinney
Mr. Erick Wayne DeVinney
Chief Innovation Officer
Chief Innovation Officer
237.78K
+18.45%
Mr. Erick Wayne DeVinney
Mr. Erick Wayne DeVinney
Chief Innovation Officer
Chief Innovation Officer
237.78K
+18.45%
Mr. Erick Wayne DeVinney
Mr. Erick Wayne DeVinney
Chief Innovation Officer
Chief Innovation Officer
237.78K
+18.45%
Mr. Jens Schroeder Kemp
Mr. Jens Schroeder Kemp
Chief Marketing Officer
Chief Marketing Officer
64.95K
-6.16%
Mr. Jens Schroeder Kemp
Mr. Jens Schroeder Kemp
Chief Marketing Officer
Chief Marketing Officer
64.95K
-6.16%
Mr. Jens Schroeder Kemp
Mr. Jens Schroeder Kemp
Chief Marketing Officer
Chief Marketing Officer
64.95K
-6.16%

FAQs

Who are the top five shareholders of AxoGen Inc?

The top five shareholders of AxoGen Inc are: Mr. Erick Wayne DeVinney

How many institutions hold shares of AxoGen Inc (AXGN)?

As of 2026Q1, 399 institutions hold shares of AxoGen Inc, with a combined market value of approximately 48.71M, accounting for 91.60% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 3148593.00.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.